Neurology · Clinical trials
Neuromyelitis Optica Spectrum Disorder (NMOSD) Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About neuromyelitis optica spectrum disorder (nmosd) — and why its trials are hard
Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune inflammatory disease of the central nervous system that preferentially attacks the optic nerves and spinal cord, causing recurrent optic neuritis and longitudinally extensive transverse myelitis, along with area postrema and brainstem syndromes. Most patients have pathogenic antibodies against the aquaporin-4 (AQP4) water channel on astrocytes; a seronegative subset may harbor MOG antibodies (now considered a distinct entity). Unlike multiple sclerosis, NMOSD relapses are often devastating and cumulative, making attack prevention the central therapeutic goal. Historic maintenance relied on off-label immunosuppression including rituximab, azathioprine, and mycophenolate. Between 2019 and 2020 three targeted biologics were approved for AQP4-IgG-positive disease: the complement C5 inhibitor eculizumab (PREVENT), the anti-CD19 B-cell-depleting antibody inebilizumab (N-MOmentum), and the IL-6 receptor antagonist satralizumab (SAkuraStar and SAkuraSky). Each markedly reduced relapse risk versus placebo, with time to first relapse as the pivotal endpoint, transforming long-term management of this relapsing disease.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Eculizumab (Soliris) | 2019 | AQP4-IgG-positive NMOSD, relapse prevention | PREVENT (Phase 3) | Time to first adjudicated relapse | ~94% relapse-free vs ~63% placebo at ~2 years; ~94% reduction in relapse risk (hazard ratio ~0.06) |
| Inebilizumab (Uplizna) | 2020 | AQP4-IgG-positive NMOSD, relapse prevention | N-MOmentum (Phase 2/3) | Time to first adjudicated attack | ~77% reduction in attack risk vs placebo (hazard ratio ~0.23) in AQP4+ patients; anti-CD19 B-cell depletion |
| Satralizumab (Enspryng) | 2020 | AQP4-IgG-positive NMOSD, relapse prevention (monotherapy or add-on) | SAkuraStar (monotherapy) and SAkuraSky (add-on) | Time to first protocol-defined relapse | ~55–74% reduction in relapse risk vs placebo in AQP4+ patients; IL-6 receptor antagonist, subcutaneous |
| Rituximab (Rituxan (off-label)) | off-label, long-established | Relapse prevention (off-label maintenance) | RIN-1 (Phase 2/3, Japan) and observational cohorts | Relapse-free rate | Widely used anti-CD20 B-cell-depleting therapy; RIN-1 showed relapse reduction, though not FDA-approved for NMOSD |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in neuromyelitis optica spectrum disorder (nmosd) development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Interferon beta / MS disease-modifying therapies — Observational and case series | Ineffective or harmful | MS therapies such as interferon-beta, natalizumab, and fingolimod can worsen NMOSD, underscoring that it is a distinct disease requiring different treatment. |
Choosing the right endpoint
Primary endpoints that matter in neuromyelitis optica spectrum disorder (nmosd) trials
- Time to first relapse/attack — The pivotal primary endpoint across PREVENT, N-MOmentum, and the SAkura trials; adjudicated by an independent committee.
- Annualized relapse rate (ARR) — Secondary measure of attack frequency reduction over the trial period.
- EDSS (Expanded Disability Status Scale) — Tracks cumulative neurological disability, which in NMOSD accrues mainly from attacks.
- Visual function / low-contrast acuity — Captures optic-neuritis-related vision loss, a major driver of NMOSD morbidity.
- Proportion relapse-free — Clinically intuitive endpoint reported alongside hazard ratios in the pivotal trials.
How iNGENū runs neuromyelitis optica spectrum disorder (nmosd) trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Neuromyelitis Optica Spectrum Disorder (NMOSD) clinical trials — FAQs
How is NMOSD different from multiple sclerosis?
What is the goal of NMOSD treatment?
Are the approved drugs only for AQP4-positive patients?
Ready to discuss your neuromyelitis optica spectrum disorder (nmosd) trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal